Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05108558 · ClinicalTrials.gov registry record · Phase 4

Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders

A Phase 4 study of Peyronie's Disease, sponsored by Charitable Union for the Research and Education of Peyronie's Disease.

Active
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT05108558 is a Phase 4 study of Peyronie's Disease that is active but no longer recruiting, run by Charitable Union for the Research and Education of Peyronie's Disease. The registered enrollment target is 40 participants, below the 182-participant average among 5 other Peyronie's Disease trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05108558, a Phase 4 study of Peyronie's Disease, is active but no longer recruiting, sponsored by Charitable Union for the Research and Education of Peyronie's Disease.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Compare key clinical outcomes between controls and men treated with a novel CCH administration protocol among men previously unresponsive to CCH administration.

Conditions Studied

Interventions

  • DEVICE RestoreX
  • DRUG CCH administration
  • DRUG Control - Crossover to CCH

Study Locations (1)

Utah

  • The Male Fertility and Peyronie's Clinic - Orem

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-09-20
Est. Completion 2028-09-20
Phase Phase 4

What the Registry Record Tells You About NCT05108558

The ClinicalTrials.gov registry entry for NCT05108558 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 5 other Peyronie's Disease trials with a reported enrollment target (78% lower). The listed sponsor is Charitable Union for the Research and Education of Peyronie's Disease, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peyronie's Disease appearing as the primary indexed condition, and to 3 interventions - of which RestoreX is the first listed.

NCT05108558 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT05108558 about?

NCT05108558 is a clinical study titled "Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders". Compare key clinical outcomes between controls and men treated with a novel CCH administration protocol among men previously unresponsive to CCH administration.

What is the current status of trial NCT05108558?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2021-09-20. Estimated completion is 2028-09-20.

What conditions does trial NCT05108558 study?

This clinical trial studies the following conditions: Peyronie's Disease.

What interventions are being tested in trial NCT05108558?

The interventions under investigation include: RestoreX (DEVICE), CCH administration (DRUG), Control - Crossover to CCH (DRUG).

Who is sponsoring clinical trial NCT05108558?

This trial is sponsored by Charitable Union for the Research and Education of Peyronie's Disease, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05108558 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peyronie's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.